Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
With
Cystic Fibrosis Foundation
A noninvasive assessment of hepatic fibrosis is desperately needed to advance the care of children with CF significant liver disease and to provide for measurements during clinical trials. That global assessment might serve as both a predictor/descriptor of disease course but also as a critical biomarker for clinical research. FibroScan® measurement of liver stiffness has great potential to fill this void. The underlying hypothesis of this proposal is that elastography in addition to US can improved the prediction of the development of a nodular liver on US and development of portal hypertension over time in children and young adults with CF.
Age
6–26
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Participants enrolled in CFLD NET PUSH study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
Entry criteria for that study were:
CF as determined by sweat chloride \>60 meq/l
Pancreatic insufficiency
Age 3-12 years old at entry
For entry into the longitudinal follow up subjects were in one of two groups
* A screening US pattern of nodular liver (CIR), heterogeneous increased echogenicity (HTG) or homogeneous increased echogenicity (HMG)
* A screening US pattern of normal (NL) matched to a HTG subject (2 NL:1HTG) by age, center and pseudomonas status
You may not be if
Exited from the PUSH Study
Unable / unwilling to sign consent
Clareo Health | Longitudinal Assessment of Transient Elastography in Cystic Fibrosis
